Effects of muzolimine and of a combination of hydrochlorothiazide/triamterene in healthy subjects and in nephrotic patients.
The diuretic effects of 30 mg muzolimine and 25 mg hydrochlorothiazide/50 mg triamterene were comparable in healthy subjects and nephrotic patients (serum albumin less than 32 g/l, creatinine clearance greater than 50 ml/min/1.73 m2). A single daily dose of 30 mg muzolimine or 25 mg hydrochlorothiazide/50 mg triamterene was sufficient in the majority of the investigated nephrotic patients. The different diuretic effects which were observed in nephrotic patients were not related to the severity of hypalbuminemia, but rather to differences in preceding diuretic treatment. Plasma levels and urinary excretion of unchanged muzolimine were comparable in healthy subjects and nephrotic patients after one day of diuretic treatment; after seven days of treatment plasma levels of muzolimine were significantly lower and urinary excretion significantly higher in nephrotic patients than in control subjects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001835:Body Weight / Q000187:drug effects; D003404:Creatinine / Q000652:urine; D004359:Drug Therapy, Combination; D004573:Electrolytes / Q000378:metabolism; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009156:Muzolimine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D011507:Proteinuria / Q000652:urine; D011720:Pyrazoles / Q000627:therapeutic use*; D014223:Triamterene / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D004573:Electrolytes; D011720:Pyrazoles; D009156:Muzolimine; D006852:Hydrochlorothiazide; D003404:Creatinine; D014223:Triamterene